• 

  Beyond the Hype: What Does the Lecanemab News Mean for People with Alzheimer’s?
• 

  Celebrating Anti-Dementia Stigma Initiatives Across Europe
• 

  When People With Alzheimer’s Stop Eating
• 

  Cuba Has an Experimental Alzheimer’s Drug In Human Trials
• 

  A New Kind of Alzheimer’s Drug, AD101, Makes Its Way
• 

  Meet Eli Lilly’s New Phase 3 Alzheimer’s Drug, Remternetug
• 

  Why Some Researchers Are Calling Alzheimer’s “Type 3 Diabetes”
• 

  Dementia Get-Together: The Rise of the Memory Cafe
• 

  First-Ever Drug for Alzheimer’s Agitation, Brexpiprazole, Nears Finish Line
• 

  Alzheimer’s and Anger: Your Questions, Answered
• 

  With Tech, a Nigerian Artist Brings ‘Spark’ to Care Homes
• 

  Deborah Kan: Dispatch from CTAD 2022
• 

  CTAD: Lecanemab On Track to File for FDA Approval In Early 2023
• 

  Natural Supplements for Alzheimer’s Disease
• 

  Phil’s Journal: A Note on Gratitude and Giving

Previous575859Next